Previous 10 | Next 10 |
2023-11-22 09:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference on November 30, 2023, at 1:00 p.m. ET. A webcast of the presentation may be accessed on the Events and Presen...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal year ended September 30, 2023. Webcast and Conference Call and Details Investors may acce...
- Plozasiran achieved mean max reductions of up to 90% in APOC3 and 87% in triglycerides in patients with severe hypertriglyceridemia - In patients with mixed dyslipidemia, mean max reduction in APOC3 was up to 89% leading to robust and durable reductions in multiple atherogenic lipoproteins ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on November 16, 2023, at 13:30 GMT. A webcast of the presentation may be accessed on the Events and Presentations pa...
- Company will also host a virtual analyst and investor event on November 13, 2023 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zo...
2023-10-31 10:31:16 ET More on Arrowhead Pharma Arrowhead Pharmaceuticals: A High-Risk, High-Reward Bet Arrowhead Remains Well-Positioned For RNAi-Based Therapeutic Breakthroughs Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2023 Earnings Call Transcript Ionis la...
2023-10-29 23:51:13 ET Summary Novartis recently completed the spin-off of Sandoz which improved its growth and margin profile. The biopharma business is in good shape with a decent collection of high-growth products and pipeline opportunities. The recent share price correctio...
2023-10-26 01:47:29 ET Summary Arrowhead Pharmaceuticals presents a complex investment opportunity with substantial risks and significant growth prospects. Despite revenue volatility and escalating operational costs, the company has a strong cash reserve and partnerships for finan...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2023 Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting – October 4-6, 2023 Date: October 5, 2023 Type: Poster Presentat...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...